Advertisement
U.S. Markets open in 6 hrs 58 mins

Aerovate Therapeutics, Inc. (AVTE)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Visitors trend2W10W9M
2.3400-0.0300 (-1.27%)
At close: 04:00PM EDT
2.3400 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.3700
Open2.3700
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.2905 - 2.3700
52 Week Range1.2500 - 32.4150
Volume93,075
Avg. Volume250,029
Market Cap67.55M
Beta (5Y Monthly)1.03
PE Ratio (TTM)N/A
EPS (TTM)-3.1300
Earnings DateAug 12, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.33
  • GlobeNewswire

    Aerovate Therapeutics to Explore Strategic Alternatives

    WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) as well as the long-term extension study, today announced that it will conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value. As part of this review process, Aerovate has engaged Wedbush PacG

  • BioPharma Dive

    Ligand to buy Apeiron; Roche reports another TIGIT setback

    Acquiring Apeiron will hand Ligand royalty rights on the neuroblastoma drug Qarziba. Elsewhere, CSL reported the first commercial treatment of patients in Europe with its gene therapy Hemgenix.